-+ 0.00%
-+ 0.00%
-+ 0.00%

Vir Biotechnology says FDA grants Fast Track status to prostate cancer drug VIR-5500

PUBT·10/08/2026 12:41:17
Vir Biotechnology says FDA grants Fast Track status to prostate cancer drug VIR-5500
  • Vir Biotechnology’s VIR-5500 won FDA Fast Track designation for late-line metastatic castration-resistant prostate cancer.
  • Program is co-developed with Astellas under a global collaboration.
  • Vir expects to start pivotal Phase 3 trials in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-065408), on October 08, 2026, and is solely responsible for the information contained therein.